Search

Your search keyword '"Nofziger, Ryan A"' showing total 137 results
Start Over Author "Nofziger, Ryan A"
137 results on '"Nofziger, Ryan A"'

1. Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.

Author

Zambrano, Laura, Newhams, Margaret, Simeone, Regina, Payne, Amanda, Wu, Michael, Orzel-Lockwood, Amber, Halasa, Natasha, Calixte, Jemima, Pannaraj, Pia, Mongkolrattanothai, Kanokporn, Boom, Julie, Sahni, Leila, Kamidani, Satoshi, Chiotos, Kathleen, Cameron, Melissa, Maddux, Aline, Irby, Katherine, Schuster, Jennifer, Mack, Elizabeth, Biggs, Austin, Coates, Bria, Michelson, Kelly, Bline, Katherine, Nofziger, Ryan, Crandall, Hillary, Hobbs, Charlotte, Gertz, Shira, Heidemann, Sabrina, Bradford, Tamara, Walker, Tracie, Schwartz, Stephanie, Staat, Mary, Bhumbra, Samina, Hume, Janet, Kong, Michele, Stockwell, Melissa, Connors, Thomas, Cullimore, Melissa, Flori, Heidi, Levy, Emily, Cvijanovich, Natalie, Zinter, Matt, Maamari, Mia, Bowens, Cindy, Zerr, Danielle, Guzman-Cottrill, Judith, Gonzalez, Ivan, Campbell, Angela, and Randolph, Adrienne

Subjects
Humans, Adolescent, Child, United States, COVID-19 Vaccines, COVID-19, mRNA Vaccines, Vaccine Efficacy, SARS-CoV-2, Hospitalization, RNA, Messenger
Abstract

Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection of the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with updated COVID-19 vaccines. During December 19, 2021-October 29, 2023, the Overcoming COVID-19 Network evaluated vaccine effectiveness (VE) of ≥2 original monovalent COVID-19 mRNA vaccine doses against COVID-19-related hospitalization and critical illness among U.S. children and adolescents aged 5-18 years, using a case-control design. Too few children and adolescents received bivalent or updated monovalent vaccines to separately evaluate their effectiveness. Most case-patients (persons with a positive SARS-CoV-2 test result) were unvaccinated, despite the high frequency of reported underlying conditions associated with severe COVID-19. VE of the original monovalent vaccine against COVID-19-related hospitalizations was 52% (95% CI = 33%-66%) when the most recent dose was administered

Published
2024

2. Characteristics and Clinical Outcomes of Vaccine-Eligible US Children Under-5 Years Hospitalized for Acute COVID-19 in a National Network.

Author

Zambrano, Laura, Newhams, Margaret, Simeone, Regina, Fleming-Dutra, Katherine, Halasa, Natasha, Wu, Michael, Orzel-Lockwood, Amber, Kamidani, Satoshi, Pannaraj, Pia, Chiotos, Kathleen, Cameron, Melissa, Maddux, Aline, Schuster, Jennifer, Crandall, Hillary, Kong, Michele, Nofziger, Ryan, Staat, Mary, Bhumbra, Samina, Irby, Katherine, Boom, Julie, Sahni, Leila, Hume, Janet, Gertz, Shira, Maamari, Mia, Bowens, Cindy, Levy, Emily, Bradford, Tamara, Walker, Tracie, Schwartz, Stephanie, Mack, Elizabeth, Guzman-Cottrill, Judith, Hobbs, Charlotte, Zinter, Matt, Cvijanovich, Natalie, Bline, Katherine, Hymes, Saul, Campbell, Angela, and Randolph, Adrienne

Subjects
Child, Humans, Child, Preschool, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Hospitalization, Vaccination
Abstract

BACKGROUND AND OBJECTIVES: In June 2022, the mRNA COVID-19 vaccination was recommended for young children. We examined clinical characteristics and factors associated with vaccination status among vaccine-eligible young children hospitalized for acute COVID-19. METHODS: We enrolled inpatients 8 months to

Published
2024

3. NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2–related complications

Author

Bodansky, Aaron, Vazquez, Sara E, Chou, Janet, Novak, Tanya, Al-Musa, Amer, Young, Cameron, Newhams, Margaret, Kucukak, Suden, Zambrano, Laura D, Mitchell, Anthea, Wang, Chung-Yu, Moffitt, Kristin, Halasa, Natasha B, Loftis, Laura L, Schwartz, Stephanie P, Walker, Tracie C, Mack, Elizabeth H, Fitzgerald, Julie C, Gertz, Shira J, Rowan, Courtney M, Irby, Katherine, Sanders, Ronald C, Kong, Michele, Schuster, Jennifer E, Staat, Mary A, Zinter, Matt S, Cvijanovich, Natalie Z, Tarquinio, Keiko M, Coates, Bria M, Flori, Heidi R, Dahmer, Mary K, Crandall, Hillary, Cullimore, Melissa L, Levy, Emily R, Chatani, Brandon, Nofziger, Ryan, Investigators, Overcoming COVID-19 Network Study Group, Yates, Masson, Smith, Chelsea, Zinter, MattS, McLaughlin, Gwenn, Randolph, Adrienne G, Newhams, Margaret M, Moon, Hye Kyung, Kobayashi, Takuma, Melo, Jeni, Chen, Sabrina R, Behl, Supriya, Drapeau, Noelle M, McCulloh, Russell J, Nofziger, Ryan A, Staat, Mary Allen, Rohlfs, Chelsea C, Reed, Nelson, Geha, Raif S, DeRisi, Joseph, Campbell, Angela P, and Anderson, Mark

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Lung, Vaccine Related, Infectious Diseases, Rare Diseases, Pneumonia, Clinical Research, Prevention, Emerging Infectious Diseases, Biodefense, Pediatric, Genetics, Autoimmune Disease, Aetiology, 2.1 Biological and endogenous factors, Inflammatory and immune system, Good Health and Well Being, Adult, Humans, Child, Adolescent, SARS-CoV-2, COVID-19, Autoantibodies, NF-kappa B, Haploinsufficiency, Leukocytes, Mononuclear, Interferon Type I, NF-kappa B p52 Subunit, Anti-interferon autoantibody, MIS-C, NFKB2, inborn errors of immunity, Overcoming COVID-19 Network Study Group Investigators, Immunology, Allergy
Abstract

BackgroundAutoantibodies against type I IFNs occur in approximately 10% of adults with life-threatening coronavirus disease 2019 (COVID-19). The frequency of anti-IFN autoantibodies in children with severe sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is unknown.ObjectiveWe quantified anti-type I IFN autoantibodies in a multicenter cohort of children with severe COVID-19, multisystem inflammatory syndrome in children (MIS-C), and mild SARS-CoV-2 infections.MethodsCirculating anti-IFN-α2 antibodies were measured by a radioligand binding assay. Whole-exome sequencing, RNA sequencing, and functional studies of peripheral blood mononuclear cells were used to study any patients with levels of anti-IFN-α2 autoantibodies exceeding the assay's positive control.ResultsAmong 168 patients with severe COVID-19, 199 with MIS-C, and 45 with mild SARS-CoV-2 infections, only 1 had high levels of anti-IFN-α2 antibodies. Anti-IFN-α2 autoantibodies were not detected in patients treated with intravenous immunoglobulin before sample collection. Whole-exome sequencing identified a missense variant in the ankyrin domain of NFKB2, encoding the p100 subunit of nuclear factor kappa-light-chain enhancer of activated B cells, aka NF-κB, essential for noncanonical NF-κB signaling. The patient's peripheral blood mononuclear cells exhibited impaired cleavage of p100 characteristic of NFKB2 haploinsufficiency, an inborn error of immunity with a high prevalence of autoimmunity.ConclusionsHigh levels of anti-IFN-α2 autoantibodies in children and adolescents with MIS-C, severe COVID-19, and mild SARS-CoV-2 infections are rare but can occur in patients with inborn errors of immunity.

Published
2023

4. Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19-Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance - 20 States, March 9, 2022-May 31, 2023.

Author

Simeone, Regina, Zambrano, Laura, Halasa, Natasha, Fleming-Dutra, Katherine, Newhams, Margaret, Wu, Michael, Orzel-Lockwood, Amber, Kamidani, Satoshi, Pannaraj, Pia, Irby, Katherine, Maddux, Aline, Hobbs, Charlotte, Cameron, Melissa, Boom, Julie, Sahni, Leila, Kong, Michele, Nofziger, Ryan, Schuster, Jennifer, Crandall, Hillary, Hume, Janet, Staat, Mary, Mack, Elizabeth, Bradford, Tamara, Heidemann, Sabrina, Levy, Emily, Gertz, Shira, Bhumbra, Samina, Walker, Tracie, Bline, Katherine, Michelson, Kelly, Zinter, Matt, Flori, Heidi, Campbell, Angela, and Randolph, Adrienne

Subjects
Female, Pregnancy, Infant, Humans, SARS-CoV-2, COVID-19, COVID-19 Vaccines, RNA, Messenger, Stored, Case-Control Studies, Hospitalization, Mothers, Vaccination
Abstract

Infants aged

Published
2023

5. Risk factors for health impairments in children after hospitalization for acute COVID-19 or MIS-C.

Author

Maddux, Aline, Young, Cameron, Kucukak, Suden, Zambrano, Laura, Newhams, Margaret, Rollins, Caitlin, Halasa, Natasha, Gertz, Shira, Mack, Elizabeth, Schwartz, Stephanie, Kong, Michele, Loftis, Laura, Irby, Katherine, Rowan, Courtney, Tarquinio, Keiko, Zinter, Matt, Crandall, Hillary, Cvijanovich, Natalie, Schuster, Jennifer, Fitzgerald, Julie, Staat, Mary, Hobbs, Charlotte, Nofziger, Ryan, Shein, Steven, Flori, Heidi, Cullimore, Melissa, Chatani, Brandon, Levy, Emily, Typpo, Katri, Hume, Janet, Campbell, Angela, and Randolph, Adrienne

Subjects
COVID-19, COVID-19 post-intensive care syndrome, MIS-C, SARS-CoV-2, critical care outcomes, multisystem inflammatory syndrome in children, pediatrics, post-acute COVID-19 syndrome
Abstract

OBJECTIVE: To identify risk factors for persistent impairments after pediatric hospitalization for acute coronavirus disease 2019 (COVID-19) or multisystem inflammatory syndrome in children (MIS-C) during the SARS-CoV-2 pandemic. METHODS: Across 25 U.S. Overcoming COVID-19 Network hospitals, we conducted a prospective cohort study of patients

Published
2023

6. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022.

Author

Halasa, Natasha, Olson, Samantha, Staat, Mary, Newhams, Margaret, Price, Ashley, Boom, Julie, Sahni, Leila, Cameron, Melissa, Pannaraj, Pia, Bline, Katherine, Bhumbra, Samina, Bradford, Tamara, Chiotos, Kathleen, Coates, Bria, Cullimore, Melissa, Cvijanovich, Natalie, Flori, Heidi, Gertz, Shira, Heidemann, Sabrina, Hobbs, Charlotte, Hume, Janet, Irby, Katherine, Kamidani, Satoshi, Kong, Michele, Levy, Emily, Mack, Elizabeth, Maddux, Aline, Michelson, Kelly, Nofziger, Ryan, Schuster, Jennifer, Schwartz, Stephanie, Smallcomb, Laura, Tarquinio, Keiko, Walker, Tracie, Zinter, Matt, Gilboa, Suzanne, Polen, Kara, Campbell, Angela, Randolph, Adrienne, and Patel, Manish

Subjects
COVID-19, COVID-19 Vaccines, Case-Control Studies, Female, Hospitalization, Hospitals, Pediatric, Humans, Immunity, Maternally-Acquired, Immunization, Passive, Infant, Infant, Newborn, Pregnancy, SARS-CoV-2, United States, Vaccines, Synthetic, mRNA Vaccines
Abstract

COVID-19 vaccination is recommended for persons who are pregnant, breastfeeding, trying to get pregnant now, or who might become pregnant in the future, to protect them from COVID-19.§ Infants are at risk for life-threatening complications from COVID-19, including acute respiratory failure (1). Evidence from other vaccine-preventable diseases suggests that maternal immunization can provide protection to infants, especially during the high-risk first 6 months of life, through passive transplacental antibody transfer (2). Recent studies of COVID-19 vaccination during pregnancy suggest the possibility of transplacental transfer of SARS-CoV-2-specific antibodies that might provide protection to infants (3-5); however, no epidemiologic evidence currently exists for the protective benefits of maternal immunization during pregnancy against COVID-19 in infants. The Overcoming COVID-19 network conducted a test-negative, case-control study at 20 pediatric hospitals in 17 states during July 1, 2021-January 17, 2022, to assess effectiveness of maternal completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy against COVID-19 hospitalization in infants. Among 379 hospitalized infants aged

Published
2022

7. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.

Author

Zambrano, Laura, Newhams, Margaret, Olson, Samantha, Halasa, Natasha, Price, Ashley, Boom, Julie, Sahni, Leila, Kamidani, Satoshi, Tarquinio, Keiko, Maddux, Aline, Heidemann, Sabrina, Bhumbra, Samina, Bline, Katherine, Nofziger, Ryan, Hobbs, Charlotte, Bradford, Tamara, Cvijanovich, Natalie, Irby, Katherine, Mack, Elizabeth, Cullimore, Melissa, Pannaraj, Pia, Kong, Michele, Walker, Tracie, Gertz, Shira, Michelson, Kelly, Cameron, Melissa, Chiotos, Kathleen, Maamari, Mia, Schuster, Jennifer, Orzel, Amber, Patel, Manish, Campbell, Angela, and Randolph, Adrienne

Subjects
Adolescent, BNT162 Vaccine, COVID-19, Case-Control Studies, Child, Female, Hospitalization, Humans, Male, Patient Acuity, SARS-CoV-2, Systemic Inflammatory Response Syndrome, United States, Vaccine Efficacy, COVID-19 Drug Treatment
Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, which generally occurs 2-6 weeks after a typically mild or asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19 (1-3). In the United States, the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine is currently authorized for use in children and adolescents aged 5-15 years under an Emergency Use Authorization and is fully licensed by the Food and Drug Administration for persons aged ≥16 years (4). Prelicensure randomized trials in persons aged ≥5 years documented high vaccine efficacy and immunogenicity (5),§ and real-world studies in persons aged 12-18 years demonstrated high vaccine effectiveness (VE) against severe COVID-19 (6). Recent evidence suggests that COVID-19 vaccination is associated with lower MIS-C incidence among adolescents (7); however, VE of the 2-dose Pfizer-BioNTech regimen against MIS-C has not been evaluated. The effectiveness of 2 doses of Pfizer-BioNTech vaccine received ≥28 days before hospital admission in preventing MIS-C was assessed using a test-negative case-control design¶ among hospitalized patients aged 12-18 years at 24 pediatric hospitals in 20 states** during July 1-December 9, 2021, the period when most MIS-C patients could be temporally linked to SARS-CoV-2 B.1.617.2 (Delta) variant predominance. Patients with MIS-C (case-patients) and two groups of hospitalized controls matched to case-patients were evaluated: test-negative controls had at least one COVID-19-like symptom and negative SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) or antigen-based assay results, and syndrome-negative controls were hospitalized patients without COVID-19-like illness. Among 102 MIS-C case-patients and 181 hospitalized controls, estimated effectiveness of 2 doses of Pfizer-BioNTech vaccine against MIS-C was 91% (95% CI = 78%-97%). All 38 MIS-C patients requiring life support were unvaccinated. Receipt of 2 doses of the Pfizer-BioNTech vaccine is associated with a high level of protection against MIS-C in persons aged 12-18 years, highlighting the importance of vaccination among all eligible children.

Published
2022

8. NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2–related complications

Author

Kong, Michele, Sanders, Ronald C., Jr., Yates, Masson, Smith, Chelsea, Cvijanovich, Natalie Z., Zinter, MattS., McLaughlin, Gwenn, Tarquinio, Keiko M., Coates, Bria M., Rowan, Courtney M., Randolph, Adrienne G., Newhams, Margaret M., Kucukak, Suden, Novak, Tanya, Moon, Hye Kyung, Kobayashi, Takuma, Melo, Jeni, Young, Cameron, Chen, Sabrina R., Chou, Janet, Flori, Heidi R., Dahmer, Mary K., Levy, Emily R., Behl, Supriya, Drapeau, Noelle M., Schuster, Jennifer E., Cullimore, Melissa L., McCulloh, Russell J., Gertz, Shira J., Schwartz, Stephanie P., Walker, Tracie C., Nofziger, Ryan A., Staat, Mary Allen, Rohlfs, Chelsea C., Fitzgerald, Julie C., Mack, Elizabeth H., Reed, Nelson, Halasa, Natasha B., Loftis, Laura L., Crandall, Hillary, Bodansky, Aaron, Vazquez, Sara E., Al-Musa, Amer, Newhams, Margaret, Zambrano, Laura D., Mitchell, Anthea, Wang, Chung-Yu, Moffitt, Kristin, Irby, Katherine, Staat, Mary A., Zinter, Matt S., Chatani, Brandon, Nofziger, Ryan, Geha, Raif S., DeRisi, Joseph, Campbell, Angela P., and Anderson, Mark

Published
2023
Full Text
View/download PDF

9. Immunocompromised-Associated Pediatric Acute Respiratory Distress Syndrome: Experience From the 2016/2017 Pediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology Prospective Cohort Study*

Author

Gertz, Shira J., Bhalla, Anoopindar, Chima, Ranjit S., Emeriaud, Guillaume, Fitzgerald, Julie C., Hsing, Deyin D., Jeyapalan, Asumthia S., Pike, Francis, Sallee, Colin J., Thomas, Neal J., Yehya, Nadir, Rowan, Courtney M., Sforza, Jesica, Poterala, Rossana, Fernandez, Analia, Avila Vera, Antonio, Orqueda, Daniel, Agueda Vidal, Nilda, Rosemary, Deheza, Turon, Gonzalo, Monjes, Cecilia, Fernando Espanol, Segundo, Siaba Serrate, Alejandro, Iolster, Thomas, Torres, Silvio, Cinquegrani, Karina, Jose Montes, Maria, Capocasa, Patricia, Ferreyra, Marcela, Castellani, Pablo, Giampieri, Martin, Pedraza, Claudia, Martin Landry, Luis, Althabe, Maria, Vanesa Fortini, Yanina, Botta, Priscila, Paziencia, Fernando, Erickson, Simon, Barr, Samantha, Shea, Sara, Butt, Warwick, Delzoppo, Carmel, Pintimalla, Alyssa, Martinez Leon, Alejandro Fabio, Guzman Rivera, Gustavo Alfredo, Jouvet, Philippe, Emeriaud, Guillaume, Dumitrascu, Mariana, Ellen French, Mary, Caro, Daniel, Castillo, I, Andres, E., Cruces Romero, Pablo, Medina, Tania, Pavez Madrid, Paula, Cortez, Ambar, Alvear, Jimena, Acuna, Carlos, Diaz, Franco, Jose Nunez, Maria, Wegner Araya, Adriana, Godoy Mundaca, Loreto, Chen, Yang, Perez Lozano, German, Pardo Carrero, Rosalba, Lopez Alarcon, Yurika Paola, Mazzillo Vega, Liliana, Maria Izquierdo, Ledys, Piñeres Olave, Byron Enrique, Zuluaga Orrego, Cesar, Quinonez Lopez, Deyanira, Vasquez Hoyos, Pablo, Vavrina, Martin, Zurek, Jiri, Campos-Miño, Santiago, Yerovi, Rocio, Bridier, Armelle, Payen, Valerie, Milesi, Christophe, Bourgoin, Pierre, Travert, Brendan, Genuini, Mathieu, Starck, Julie, Maria, Matthieu, Guichoux, Julie, Baudin, Florent, Briassoulis, George, Ilia, Stavroula, Di Nardo, Matteo, Camporesi, Anna, Chiusolo, Fabrizio, Shime, Nobuaki, Ohshimo, Shinichiro, Kida, Yoshiko, Kyo, Michihito, Tabata, Yuichi, Fong Tang, Swee, Wern Tai, Chian, See Lum, Lucy Chai, Elghuwael, Ismail, Jimenez Rivera, Nestor Javier, Jarillo Quijada, Alberto E, Kneyber, Martin, Dijkstra, Sandra, Beca, John, Sherring, Claire, Miriam, Rea, Vargas G, Sonia I, Vasquez Miranda, Daniel, Ramirez Cortez, Grimaldo, Tantalean, Jose, Pagowska-Klimek, Izabela, Gil Escobar, Carlos, Sousa Moniz, Marta, Camilo, Cristina, Hazwani, Tarek, Aldairi, Nedaa, Al Amoudi, Ahmed, Alahmadti, Ahmad, Taylor, Ryan, Mendizabal, Mikel, Goni Orayen, Concepcion, Lopez Fernandez, Yolanda, Ramon Valle, Juan, Martinez, Lidia, Pilar Orive, Javier, Brezmes, Marta, Lopez-Herce, Jesus, Parrilla, Julio, Gaboli, Mirella, Gonzalez Gomez, Jose Manuel, Morales Martinez, Antonio, Alapont, Vicent Modesto I, Sanchez Diaz, Juan Ignacio, Llorente de la Fuente, Ana M., Palanca Arias, Daniel, Madurga Revilla, Paula, Martinez de Azagra, Amelia, Garcia Gonzalez, Maria, Arjona Villanueva, David, Garcia Casas, Paula, Brio Sanagustin, Sonia, Pons Odena, Marti, Medina, Alberto, Onate Vergara, Eider, Rodriguez Campoy, Patricia, Reyes Dominguez, Susana, Dursun, Oguz, Atike Ongun, Ebru, Kamit Can, Fulya, Berna Anil, Ayse, Baines, Paul, Walsh, Laura, Jones, Dawn, Sadasivam, Kalaimaran, Mildner, Reinout, Plunkett, Adrian, Lillie, Jon, Tibby, Shane, Wellman, Paul, Belfield, Holly, Brierley, Joe, Dominguez, Troy E., Abaleke, Eugenia, Feinstein, Yael, Deep, Akash, Sundararajan, Santosh, Oruganti, Siva, Silvestre, Catarina, Weitz, James, Sheward, Victoria, Macrae, Duncan, Aramburo, Angela, Fortune, Peter-Marc, Subramanian, Gayathri, Jennings, Claire, Dwarakanathan, Buvana, Inwald, David, Feather, Calandra, Agbeko, Rachel, Lawton-Woodhall, Angela, McIntyre, Karen, Sykes, Kim, Pappachan, Jon, Gale, Helen, Mellish, Christie, McCorkell, Jenni, Torero, Luis, Nofziger, Ryan, Latifi, Samir, Anthony, Heather, Sanders, Ron, Hefley, Glenda, Virk, Manpreet, Jaimon, Nancy, Maddux, Aline B., Mourani, Peter M., Ralston, Kimberly, Sierra, Yamila, Khemani, Robinder, Newth, Christopher, Bhalla, Anoopindar, Kwok, Jeni, Morzov, Rica, Mahapatra, Sidharth, Truemper, Edward, Kustka, Lucinda, Nett, Sholeen T., Singleton, Marcy, Dean Jarvis, J., Yehya, Nadir, Napolitano, Natalie, Murphy, Marie, Ronan, Laurie, Morgan, Ryan, Kubis, Sherri, Broden, Elizabeth, Willson, Douglas, Henderson, Grace, Gedeit, Rainer, Murkowski, Kathy, Woods, Katherine, Kasch, Mary, Han, Yong Y, Affolter, Jeremy T, Tieves, Kelly S, Hughes-Schalk, Amber, Chima, Ranjit S., Krallman, Kelli, Stoneman, Erin, Benken, Laura, Yunger, Toni, Schneider, James, Sweberg, Todd, Kessel, Aaron, Carroll, Christopher L., Santanelli, James, Ackerman, Kate G, Cullimore, Melissa, Rowan, Courtney, Bales, Melissa, Keith Dockery, W., Jafari-Namin, Shirin, Barry, Dana, Jane’t, Keary, Alibrahim, Omar, Patankar, Nikhil, Qiao, Haiping, Gertz, Shira, Su, Felice, Haileselassie, Bereketeab, Song, Hanqiu, Bysani, Kris, Monjure, Tracey, Beltramo, Fernando, Totapally, Balagangadhar, Govantes, Beatriz, Coates, Bria, Wellisch, Lawren, Allen, Kiona, Shukla, Avani, Thomas, Neal J., Spear, Debbie, Shein, Steven L., Gertz, Shira, Parker, Margaret M., Sloniewsky, Daniel, Allen, Christine, Harrell, Amy, Pinto, Neethi, Kniola, Allison, Rodgers, Chiara, Cvijanovich, Natalie, Typpo, Katri, Kelley, Connor, King, Caroline, Sapru, Anil, Ratiu, Anna, Ashtari, Neda, Sikora, Lindsay, Jeyapalan, Asumthia S., Coronado-Munoz, Alvaro, Flori, Heidi, Dahmer, Mary K., Jayachandran, Chaandini, Hume, Janet, Nerheim, Dan, Smith, Rebecca, Spaeder, Michael, Adu-Darko, Michelle, Smith, Lincoln, Hartmann, Silvia, Sullivan, Erin, Merritt, Courtney, Al-Subu, Awni, Blom, Andrea, Lin, John C., Spinella, Philip, Hsing, Deyin D., Pon, Steve, Brian Estil, Jim, Gautam, Richa, Giuliano, John S., Jr, and Tala, Joana

Published
2024
Full Text
View/download PDF

10. Prevalence of Bacterial Codetection and Outcomes for Infants Intubated for Respiratory Infections

Author

Karsies, Todd, Shein, Steven L., Diaz, Franco, Vasquez-Hoyos, Pablo, Alexander, Robin, Pon, Steven, González-Dambrauskas, Sebastián, Yock-Corrales, Adriana, Rotta, Alex, Prout, Andrew, Wen, Andrew, Camporesi, Anna, Vargas, Arieth Figueroa, Coates, Bria, Piñeres-Olave, Byron Enrique, Stulce, Casey, Watson, Christopher, Francoeur, Conall, Cantillano, Edwin Mauricio, Zemanete, Eliana, Castro, Francisca, Yague, Gema Perez, Ozdemir, Goktug, Chandnani, Harsha, Harwayne-Gidansky, Ilana, Cinquegrani, Karina, Izquierdo, Ledys, Polikoff, Lee, Valero, Leonardo, Gaspers, Mary, Maamari, Mia, Kangin, Murat, Rodriguez, Nils Casson, Ozturk, Nilufer, Castellani, Pablo, Khandhar, Paras, Jabornisky, Roberto, Arana, Rosa, Pardo, Rosalba, Palomino, Rubén Lasso, Nofziger, Ryan, Torales, Santiago Ayala, Ambati, Shashikanth, Gertz, Shira, Jeyapalan, Simi, Murthy, Srinivas, Muisyo, Teddy, Lillitwat, Weerapong, and Lopez-Alarcon, Yurika

Published
2024
Full Text
View/download PDF

11. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021.

Author

Olson, Samantha, Newhams, Margaret, Halasa, Natasha, Price, Ashley, Boom, Julie, Sahni, Leila, Irby, Katherine, Walker, Tracie, Schwartz, Stephanie, Pannaraj, Pia, Maddux, Aline, Bradford, Tamara, Nofziger, Ryan, Boutselis, Benjamin, Cullimore, Melissa, Mack, Elizabeth, Schuster, Jennifer, Gertz, Shira, Cvijanovich, Natalie, Kong, Michele, Cameron, Melissa, Staat, Mary, Levy, Emily, Chatani, Brandon, Chiotos, Kathleen, Zambrano, Laura, Campbell, Angela, Patel, Manish, and Randolph, Adrienne

Subjects
Adolescent, COVID-19, COVID-19 Vaccines, Child, Female, Hospitalization, Humans, Male, United States, Vaccines, Synthetic, mRNA Vaccines
Abstract

Pfizer-BioNTech COVID-19 vaccine is authorized for use in children and adolescents aged 12-15 years and is licensed by the Food and Drug Administration (FDA) for persons aged ≥16 (1). A randomized placebo-controlled trial demonstrated an efficacy of 100% (95% confidence interval [CI] = 75.3%-100%) in preventing outpatient COVID-19 in persons aged 12-15 years (2); however, data among adolescents on vaccine effectiveness (VE) against COVID-19 in real-world settings are limited, especially among hospitalized patients. In early September 2021, U.S. pediatric COVID-19 hospitalizations reached the highest level during the pandemic (3,4). In a test-negative, case-control study at 19 pediatric hospitals in 16 states during June 1-September 30, 2021, the effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was assessed among children and adolescents aged 12-18 years. Among 464 hospitalized persons aged 12-18 years (179 case-patients and 285 controls), the median age was 15 years, 72% had at least one underlying condition, including obesity, and 68% attended in-person school. Effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was 93% (95% CI = 83%-97%), during the period when B.1.617.2 (Delta) was the predominant variant. This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine are highly effective at preventing COVID-19 hospitalization among persons aged 12-18 years and reinforces the importance of vaccination to protect U.S. youths against severe COVID-19.

Published
2021

13. Characteristics and Clinical Outcomes of Vaccine-Eligible US Children Under-5 Years Hospitalized for Acute COVID-19 in a National Network

Author

Zambrano, Laura D., Newhams, Margaret M., Simeone, Regina M., Fleming-Dutra, Katherine E., Halasa, Natasha, Wu, Michael, Orzel-Lockwood, Amber O., Kamidani, Satoshi, Pannaraj, Pia S., Chiotos, Kathleen, Cameron, Melissa A., Maddux, Aline B., Schuster, Jennifer E., Crandall, Hillary, Kong, Michele, Nofziger, Ryan A., Staat, Mary A., Bhumbra, Samina S., Irby, Katherine, Boom, Julie A., Sahni, Leila C., Hume, Janet R., Gertz, Shira J., Maamari, Mia, Bowens, Cindy, Levy, Emily R., Bradford, Tamara T., Walker, Tracie C., Schwartz, Stephanie P., Mack, Elizabeth H., Guzman-Cottrill, Judith A., Hobbs, Charlotte V., Zinter, Matt S., Cvijanovich, Natalie Z., Bline, Katherine E., Hymes, Saul R., Campbell, Angela P., Randolph, Adrienne G., Murdock, Meghan, Kelley, Heather, Sanders, Ronald C., Miron, Laura, Barkely, Hannah, Jumarang, Jaycee, Hakimi, Daniel, Niell, Liria Muriscot, Baig, Natasha, Temte, Elizabeth, Thayer, Imogene, Petruccelli, Lexi, Zorensky, Frances, Sierra, Yamila, Gonzalez, Mark D., Ciric, Caroline R., Choi, Jong-Ha C., Baida, Nadine, Randolph, Adrienne G., Kucukak, Suden, Listerud, Eve, Clark, Maya, Dittrich, Rylie, Johnson, Brandi A., Drapeau, Noelle M., Martin, Lora, Malloch, Lacy, Martin, Maygan, Sanders, Cameron, Patterson, Kayla, Sullivan, Melissa, Pruitt, Shannon, Hymes, Saul, Harwayne-Gidansky, Ilana, Rohlfs, Chelsea C., Wolfe, Amber, Phengchomphet, Kathlyn, Bush, Jenny, Mohammed, Fatima A., Stewart, Laura S., Fernandez, Kailee, Abojaib, Leenah, Kyles, Molly J., and Campbell, Angela P.

Published
2023
Full Text
View/download PDF

14. The Modified Clinical Progression Scale for Pediatric Patients: Evaluation as a Severity Metric and Outcome Measure in Severe Acute Viral Respiratory Illness

Author

Leland, Shannon B., Staffa, Steven J., Newhams, Margaret M., Khemani, Robinder G., Marshall, John C., Young, Cameron C., Maddux, Aline B., Hall, Mark W., Weiss, Scott L., Schwarz, Adam J., Coates, Bria M., Sanders, Ronald C., Jr, Kong, Michele, Thomas, Neal J., Nofziger, Ryan A., Cullimore, Melissa L., Halasa, Natasha B., Loftis, Laura L., Cvijanovich, Natalie Z., Schuster, Jennifer E., Flori, Heidi, Gertz, Shira J., Hume, Janet R., Olson, Samantha M., Patel, Manish M., Zurakowski, David, and Randolph, Adrienne G.

Published
2023
Full Text
View/download PDF

15. Association of Asthma With Treatments and Outcomes in Children With Critical Influenza

Author

Kong, Michele, Murdock, Meghan, Sanders, Ronald C., Jr., Irby, Katherine, Hefley, Glenda, Maddux, Aline B., Mourani, Peter M., Van, Kevin A., Mansour, Rachel, Miller, Kristen R., Grunwell, Jocelyn R., Coates, Bria M., Shukla, Avani, Chavez, Jairo, Randolph, Adrienne G., Newhams, Margaret M., Chen, Sabrina R., Jung, Emily, Flori, Heidi R., Dahmer, Mary K., Jayachandran, Chaandini, Hume, Janet R., Goertzen, Lexie, Faanes, Brittany, Schuster, Jennifer E., Bledsoe, Megan C., Clark, Shannon E., Cullimore, Melissa L., Wellman, Rachel L., Gertz, Shira J., Nofziger, Ryan A., Twinem, Nicole, Shein, Steven L., Rasal, Rajashri, Hall, Mark W., Flowers, Maggie, Steele, Lisa, Weiss, Scott L., Bush, Jenny L., Burnett, Ryan H., Thomas, Neal J., Spear, Debra, Halasa, Natasha B., Stewart, Laura S., Lynch, Tricia L., Olson, Samantha M., Patel, Manish M., Miller, Kristen, Patel, Manish, Fitzpatrick, Anne M., and Phipatanakul, Wanda

Published
2023
Full Text
View/download PDF

16. Noninvasive Ventilation for Pediatric Acute Respiratory Distress Syndrome: Experience From the 2016/2017 Pediatric Acute Respiratory Distress Syndrome Incidence and Epidemiology Prospective Cohort Study*

Author

Emeriaud, Guillaume, Pons-Òdena, Marti, Bhalla, Anoopindar K., Shein, Steven L., Killien, Elizabeth Y., Modesto i Alapont, Vicent, Rowan, Courtney, Baudin, Florent, Lin, John C., Grégoire, Gabrielle, Napolitano, Natalie, Mayordomo-Colunga, Juan, Diaz, Franco, Cruces, Pablo, Medina, Alberto, Smith, Lincoln, Khemani, Robinder G., Sforza, Jesica, Poterala, Rossana, Fernandez, Analia, Avila Vera, Antonio, Orqueda, Daniel, Agueda Vidal, Nilda, Rosemary, Deheza, Turon, Gonzalo, Monjes, Cecilia, Espanol, Segundo Fernando, Serrate, Alejandro Siaba, Iolster, Thomas, Torres, Silvio, Cinquegrani, Karina, Jose Montes, Maria, Capocasa, Patricia, Ferreyra, Marcela, Castellani, Pablo, Giampieri, Martin, Pedraza, Claudia, Landry, Luis Martin, Althabe, Maria, Fortini, Yanina Vanesa, Botta, Priscila, Paziencia, Fernando, Erickson, Simon, Barr, Samantha, Shea, Sara, Butt, Warwick, Delzoppo, Carmel, Pintimalla, Alyssa, Leon, Alejandro Fabio Martinez, Rivera, Gustavo Alfredo Guzman, Jouvet, Philippe, Emeriaud, Guillaume, Dumitrascu, Mariana, Ellen French, Mary, Caro I, Daniel, Castillo, Andres E., Romero, Pablo Cruces, Medina, Tania, Madrid, Paula Pavez, Cortez, Ambar, Alvear, Jimena, Acuna, Carlos, Diaz, Franco, Nunez, Maria Jose, Araya, Adriana Wegner, Mundaca, Loreto Godoy, Chen, Yang, Lozano, German Perez, Carrero, Rosalba Pardo, Alarcon, Yurika Paola Lopez, Vega, Liliana Mazzillo, Izquierdo, Ledys Maria, Olave, Byron Enrique Piñeres, Orrego, Cesar Zuluaga, Lopez, Deyanira Quinonez, Hoyos, Pablo Vasquez, Vavrina, Martin, Zurek, Jiri, Campos-Miño, Santiago, Yerovi, Rocio, Bridier, Armelle, Payen, Valerie, Milesi, Christophe, Bourgoin, Pierre, Travert, Brendan, Genuini, Mathieu, Starck, Julie, Maria, Matthieu, Guichoux, Julie, Baudin, Florent, Briassoulis, George, Ilia, Stavroula, Di Nardo, Matteo, Camporesi, Anna, Chiusolo, Fabrizio, Shime, Nobuaki, Ohshimo, Shinichiro, Kida, Yoshiko, Kyo, Michihito, Tabata, Yuichi, Tang, Swee Fong, Tai, Chian Wern, Lum, Lucy Chai See, Elghuwael, Ismail, Rivera, Nestor Javier Jimenez, Jarillo Quijada, Alberto E, Kneyber, Martin, Dijkstra, Sandra, Beca, John, Sherring, Claire, Rea, Miriam, Vargas G, Sonia I, Miranda, Daniel Vasquez, Cortez, Grimaldo Ramirez, Tantalean, Jose, Pagowska-Klimek, Izabela, Escobar, Carlos Gil, Moniz, Marta Sousa, Camilo, Cristina, Hazwani, Tarek, Aldairi, Nedaa, Al Amoudi, Ahmed, Alahmadti, Ahmad, Taylor, Ryan, Mendizabal, Mikel, Orayen, Concepcion Goni, Fernandez, Yolanda Lopez, Valle, Juan Ramon, Martinez, Lidia, Orive, Javier Pilar, Brezmes, Marta, Lopez-Herce, Jesus, Parrilla, Julio, Gaboli, Mirella, Gomez, Jose Manuel Gonzalez, Morales Martinez, Antonio, Alapont, Vicent Modesto I, Diaz, Juan Ignacio Sanchez, Llorente de la Fuente, Ana M., Palanca Arias, Daniel, Madurga Revilla, Paula, Martinez de Azagra, Amelia, Garcia Gonzalez, Maria, Arjona Villanueva, David, Garcia Casas, Paula, Brio Sanagustin, Sonia, Pons Odena, Marti, Medina, Alberto, Onate Vergara, Eider, Rodriguez Campoy, Patricia, Reyes Dominguez, Susana, Dursun, Oguz, Atike Ongun, Ebru, Kamit Can, Fulya, Berna Anil, Ayse, Baines, Paul, Walsh, Laura, Jones, Dawn, Sadasivam, Kalaimaran, Mildner, Reinout, Plunkett, Adrian, Lillie, Jon, Tibby, Shane, Wellman, Paul, Belfield, Holly, Brierley, Joe, Dominguez, Troy E., Abaleke, Eugenia, Feinstein, Yael, Deep, Akash, Sundararajan, Santosh, Oruganti, Siva, Silvestre, Catarina, Weitz, James, Sheward, Victoria, Macrae, Duncan, Aramburo, Angela, Fortune, Peter-Marc, Subramanian, Gayathri, Jennings, Claire, Dwarakanathan, Buvana, Inwald, David, Feather, Calandra, Agbeko, Rachel, Lawton-Woodhall, Angela, McIntyre, Karen, Sykes, Kim, Pappachan, Jon, Gale, Helen, Mellish, Christie, McCorkell, Jenni, Torero, Luis, Nofziger, Ryan, Latifi, Samir, Anthony, Heather, Sanders, Ron, Hefley, Glenda, Virk, Manpreet, Jaimon, Nancy, Maddux, Aline B., Mourani, Peter M., Ralston, Kimberly, Sierra, Yamila, Khemani, Robinder, Newth, Christopher, Bhalla, Anoopindar, Kwok, Jeni, Morzov, Rica, Mahapatra, Sidharth, Truemper, Edward, Kustka, Lucinda, Nett, Sholeen T., Singleton, Marcy, Dean Jarvis, J., Yehya, Nadir, Napolitano, Natalie, Murphy, Marie, Ronan, Laurie, Morgan, Ryan, Kubis, Sherri, Broden, Elizabeth, Willson, Douglas, Henderson, Grace, Gedeit, Rainer, Murkowski, Kathy, Woods, Katherine, Kasch, Mary, Han, Yong Y, Affolter, Jeremy T, Tieves, Kelly S, Hughes-Schalk, Amber, Chima, Ranjit S., Krallman, Kelli, Stoneman, Erin, Benken, Laura, Yunger, Toni, Schneider, James, Sweberg, Todd, Kessel, Aaron, Carroll, Christopher L., Santanelli, James, Ackerman, Kate G, Cullimore, Melissa, Rowan, Courtney, Bales, Melissa, Keith Dockery, W., Jafari-Namin, Shirin, Barry, Dana, Jane’t, Keary, Alibrahim, Omar, Patankar, Nikhil, Qiao, Haiping, Gertz, Shira, Su, Felice, Haileselassie, Bereketeab, Song, Hanqiu, Bysani, Kris, Monjure, Tracey, Beltramo, Fernando, Totapally, Balagangadhar, Govantes, Beatriz, Coates, Bria, Wellisch, Lawren, Allen, Kiona, Shukla, Avani, Thomas, Neal J., Spear, Debbie, Shein, Steven L., Gertz, Shira, Parker, Margaret M., Sloniewsky, Daniel, Allen, Christine, Harrell, Amy, Pinto, Neethi, Kniola, Allison, Rodgers, Chiara, Cvijanovich, Natalie, Typpo, Katri, Kelley, Connor, King, Caroline, Sapru, Anil, Ratiu, Anna, Ashtari, Neda, Sikora, Lindsay, Jeyapalan, Asumthia S., Coronado-Munoz, Alvaro, Flori, Heidi, Dahmer, Mary K., Jayachandran, Chaandini, Hume, Janet, Nerheim, Dan, Smith, Rebecca, Spaeder, Michael, Adu-Darko, Michelle, Smith, Lincoln, Hartmann, Silvia, Sullivan, Erin, Merritt, Courtney, Al-Subu, Awni, Blom, Andrea, Lin, John C., Spinella, Philip, Hsing, Deyin D., Pon, Steve, Brian Estil, Jim, Gautam, Richa, Giuliano, John S., Jr, and Tala, Joana

Published
2023
Full Text
View/download PDF

17. Paediatric critical COVID-19 and mortality in a multinational prospective cohort

Author

Nofziger, Ryan, Ambati, Shashikanth, Kendirli, Tanil, Sanders, Ronald, Polikoff, Lee, Whelan, Siobhan, Camporesi, Anna, Francoeur, Conall, Castro, Francisca, Beltrán, Claudia, Pardo, Rosalba, Vega, Gonzalo, Yunge, Mauricio, Acevedo, Lorena, Ardila, Ivan Jose, Aranguiz, Diego, Dallefeld, Samantha, Alvarez-Olmos, MarthaI, Fernandez-Sarmiento, Jaime, Figueroa-Vargas, Arieth, Valencia-Benavides, Maribel, Roa, Juan David, Lasso-Palomino, Rubén, Franceschi, Alessia, Venthur, Carina, Gonzalez-Dambrauskas, Sebastian, Ampuero, Camila, Paco-Barral, Jhovana E., Tasayco-Muñoz, Jaime, Domínguez-Rojas, Jesús, Rafael-Patricio, Francisca, Pellegrini, Solana, Zuazaga, Marcela, Brusca, Silvana, Viera, Marisa, Aguilera-Avendano, Vladmir Ivan, Alejandro, F., Martínez, L., Thelma, E., Terán, M., Coronado-Lujan, Mariela, Castro-Mancilla, Fabiola, Diaz-Rubio, Franco, Cinquegrana, Karina, Sandoval, Alicia, Gonzalez, Andrea, Zamora, Marta, Lopez-Alarcon, Yurika, Slöcker-Barrio, María, Urbano-Villaescusa, Javier, Camacho, Humberto, Mazzillo, Liliana, Giraldo, Beatriz, Suarez, Pitas, Cespedes-Lesczinsky, Miguel, Castillo, Jorge Omar, Fabris, Juan Pablo, Paladino, Carolina, Sanabria, Silvia, Urena-Chavarría, Erika, Yock-Corrales, Adriana, Quispe, Gaudi, Munaico-Abanto, Manuel, Colombo, Miriam, Blanco, Ana Carola, Pineres-Olave, Byron Enrique, Carvajal-Veas, Ricardo, Correa, Patricia, Garcia-De-Jesus, Ricardo, Ferre, Arani, Pietroboni, Pietro, Mauricio-Cantillano, Edwin, Banegas-Pineda, Linda, Casson-Rodriguez, Nils, Cavagnaro, Agustin, Wegner, Adriana, Zemanate, Eliana, Beltran-Zuñiga, Emilce, Suarez, Maria Alejandra, Quiñonez, Deyanira, Valero, Leonardo, Repetur, Alejandra, Castellani, Pablo, Bordogna, Adriana, De-la-Hoz-Pastor, Alfredo, Obando-Belalcazar, Evelyn, Prout, Andrew, Jabornisky, Roberto, Wen, Andy, Coates, Bria, Watson, Christopher, Mack, Elizabeth, Hong, Jahee, Karsies, Todd, Pon, Steven, Dapul, Heda, Shein, Steven, Kangin, Murat, Vasquez-Hoyos, Pablo, Gertz, Shira, Ducharme-Crevier, Laurence, Harwayne-Gidansky, Ilana, Fonseca-Flores, Marisol, Nunez-Enriquez, Juan Carlos, Leon-Villanueva, Armando, Maria, Ledys, Muisyo, Teddy, Spaeder, Michael, Cantillano, Edwin Mauricio, Dominguez-Rojas, Jesus, Gurbanov, Anar, Mazzillo-Vega, Liliana, and Shein, Steven L.

Published
2022
Full Text
View/download PDF

19. Maternal Vaccination and Risk of Hospitalization for Covid-19 Among Infants

Author

Halasa, Natasha B., Olson, Samantha M., Staat, Mary A., Newhams, Margaret M., Price, Ashley M., Pannaraj, Pia S., Boom, Julie A., Sahni, Leila C., Chiotos, Kathleen, Cameron, Melissa A., Bline, Katherine E., Hobbs, Charlotte V., Maddux, Aline B., Coates, Bria M., Michelson, Kelly N., Heidemann, Sabrina M., Irby, Katherine, Nofziger, Ryan A., Mack, Elizabeth H., Smallcomb, Laura, Schwartz, Stephanie P., Walker, Tracie C., Gertz, Shira J., Schuster, Jennifer E., Kamidani, Satoshi, Tarquinio, Keiko M., Bhumbra, Samina S., Maamari, Mia, Hume, Janet R., Crandall, Hillary, Levy, Emily R., Zinter, Matt S., Bradford, Tamara T., Flori, Heidi R., Cullimore, Melissa L., Kong, Michele, Cvijanovich, Natalie Z., Gilboa, Suzanne M., Polen, Kara N., Campbell, Angela P., Randolph, Adrienne G., and Patel, Manish M.

Published
2023
Full Text
View/download PDF

20. Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care.

Author

Rowan, Courtney M, LaBere, Brenna, Young, Cameron C, Zambrano, Laura D, Newhams, Margaret M, Kucukak, Suden, McNamara, Elizabeth R, Mack, Elizabeth H, Fitzgerald, Julie C, Irby, Katherine, Maddux, Aline B, Schuster, Jennifer E, Kong, Michele, Dapul, Heda, Schwartz, Stephanie P, Bembea, Melania M, Loftis, Laura L, Kolmar, Amanda R, Babbitt, Christopher J, and Nofziger, Ryan A

Subjects
PUBLIC health surveillance, PRIMARY immunodeficiency diseases, LEUKOCYTE count, HEMATOLOGIC malignancies, TRANSPLANTATION of organs, tissues, etc., PLATELET count, CRITICALLY ill, PATIENTS, IMMUNOCOMPROMISED patients, HOSPITAL care, TREATMENT effectiveness, HOSPITALS, HOSPITAL mortality, AGE distribution, SEVERITY of illness index, PEDIATRICS, INTENSIVE care units, AUTOIMMUNE diseases, LENGTH of stay in hospitals, KIDNEY diseases, COVID-19, CRITICAL care medicine, COMORBIDITY, MIXED infections, EVALUATION, CHILDREN
Abstract

Background We aimed to determine if pre-existing immunocompromising conditions (ICCs) were associated with the presentation or outcome of patients with acute coronavirus disease 2019 (COVID-19) admitted for pediatric intensive care. Methods Fifty-five hospitals in 30 US states reported cases through the Overcoming COVID-19 public health surveillance registry. Patients <21 years admitted 12 March 2020–30 December 2021 to the pediatric intensive care unit (PICU) or high-acuity unit for acute COVID-19 were included. Results Of 1274 patients, 105 (8.2%) had an ICC, including 33 (31.4%) hematologic malignancies, 24 (22.9%) primary immunodeficiencies and disorders of hematopoietic cells, 19 (18.1%) nonmalignant organ failure with solid-organ transplantation, 16 (15.2%) solid tumors, and 13 (12.4%) autoimmune disorders. Patients with ICCs were older, had more underlying renal conditions, and had lower white blood cell and platelet counts than those without ICCs, but had similar clinical disease severity upon admission. In-hospital mortality from COVID-19 was higher (11.4% vs 4.6%, P =.005) and hospitalization was longer (P =.01) in patients with ICCs. New major morbidities upon discharge were not different between those with and without ICC (10.5% vs 13.9%, P =.40). In patients with ICCs, bacterial coinfection was more common in those with life-threatening COVID-19. Conclusions In this national case series of patients <21 years of age with acute COVID-19 admitted for intensive care, existence of a prior ICCs were associated with worse clinical outcomes. Reassuringly, most patients with ICCs hospitalized in the PICU for severe acute COVID-19 survived and were discharged home without new severe morbidities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness

Author

Sanders, Ronald C., Jr., Irby, Olivia K., Hefley, Glenda, Tellez, David, Typpo, Katri, Markovitz, Barry, Flori, Heidi, Cvijanovich, Natalie, Anas, Nick, Schwarz, Adam, Vargas-Shiraishi, Ofelia, Sapru, Anil, McQuillen, Patrick, Czaja, Angela, Mourani, Peter, Paden, Matthew, Tarquinio, Keiko, Stone, Cheryl L., Wardenburg, Juliane Bubeck, Pinto, Neethi, Montgomery, Vicki, Sullivan, Janice E., Randolph, Adrienne G., Agan, Anna A., Ash, Stephanie, Mistry, Anushay, Newhams, Margaret, Kurachek, Stephen C., Doctor, Allan, Hartman, Mary, Truemper, Edward, Mahapatra, Sidharth, Dawson, Machelle, Ackerman, Kate, Daugherty, L. Eugene, Nofziger, Ryan, Shein, Steve, Hall, Mark W., Steele, Lisa, Hanson-Huber, Lisa, Thomas, Neal J., Spear, Debra, Fitzgerald, Julie, Weiss, Scott, Bush, Jenny L., Graham, Kathryn, Higgerson, Renee, Christie, LeeAnn, Loftis, Laura L., Jaimon, Nancy, Gedeit, Rainer, Murkowski, Kathy, Novak, Tanya, McDonald, Douglas R., Newhams, Margaret M., Mistry, Anushay J., Panoskaltsis-Mortari, Angela, Mourani, Peter M., Weiss, Scott L., Tarquinio, Keiko M., Hartman, Mary E., and Junger, Wolfgang G.

Published
2020
Full Text
View/download PDF

25. Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study

Author

Abaleke, Eugenia, Ackerman, Kate G, Acuña, Carlos, Adu-Darko, Michelle, Affolter, Jeremy T, Agbeko, Rachel, Al Amoudi, Ahmed, Alahmadti, Ahmad, Aldairi, Nedaa, Alibrahim, Omar, Allen, Kiona, Allen, Christine, Al-Subu, Awni, Althabe, María, Alvear, Jimena, Anil, Ayse Berna, Anthony, Heather, Aramburo, Angela, Arjona Villanueva, David, Ashtari, Neda, Ávila Vera, Antonio, Baines, Paul, Bales, Melissa, Barr, Samantha, Barry, Dana, Baudin, Florent, Beca, John, Belfield, Holly, Beltramo, Fernando, Benken, Laura, Bhalla, Anoopindar, Blom, Andrea, Botta, Priscila, Bourgoin, Pierre, Brezmes, Marta, Briassoulis, George, Bridier, Armelle, Brierley, Joe, Brio Sanagustin, Sonia, Broden, Elizabeth, Butt, Warwick, Bysani, Kris, Camilo, Cristina, Camporesi, Anna, Campos-Miño, Santiago, Can, Fulya Kamit, Capocasa, Patricia, Caro I, Daniel, Carroll, Christopher, Castellani, Pablo, Castillo, Andres E., Chen, Yang, Chima, Ranjit S., Chiusolo, Fabrizio, Cinquegrani, Karina, Coates, Bria, Coronado-Munoz, Alvaro, Cortéz, Ambar, Cruces Romero, Pablo, Cullimore, Melissa, Cvijanovich, Natalie, Dahmer, Mary K., Deep, Akash, Delzoppo, Carmel, Di Nardo, Matteo, Díaz, Franco, Dijkstra, Sandra, Dockery, W. Keith, Dominguez, Troy E., Dumitrascu, Mariana, Dursun, Oguz, Dwarakanathan, Buvana, Elghuwael, Ismail, Emeriaud, Guillaume, Erickson, Simon, Español, Segundo Fernando, Estil, Jim Brian, Feather, Calandra, Feinstein, Yael, Fernández, Analía, Ferreyra, Marcela, Flori, Heidi, Fortini, Yanina Vanesa, Fortune, Peter-Marc, French, Mary Ellen, Gaboli, Mirella, Gale, Helen, García Casas, Paula, García González, Maria, Gautam, Richa, Gedeit, Rainer, Genuini, Mathieu, Gertz, Shira, Giampieri, Martin, Gil Escobar, Carlos, Giuliano Jr, John S., Godoy Mundaca, Loreto, Goni Orayen, Concepción, Gonzalez Gomez, Jose Manuel, Govantes, Beatriz, Guichoux, Julie, Guzman Rivera, Gustavo Alfredo, Haileselassie, Bereketeab, Han, Yong Y, Harrell, Amy, Hartmann, Silvia, Hazwani, Tarek, Hefley, Glenda, Henderson, Grace, Hsing, Deyin D., Hughes-Schalk, Amber, Hume, Janet, Ilia, Stavroula, Inwald, David, Iolster, Thomas, Izquierdo, Ledys María, Jafari-Namin, Shirin, Jaimon, Nancy, Jarillo Quijada, Alberto E, Jarvis, J. Dean, Jayachandran, Chaandini, Jennings, Claire, Jeyapalan, Asumthia S., Jimenez Rivera, Nestor Javier, Jones, Dawn, Jouvet, Philippe, Kasch, Mary, Keary, Jane't, Kelley, Connor, Kessel, Aaron, Khemani, Robinder, Kida, Yoshiko, King, Caroline, Kneyber, Martin, Kniola, Allison, Krallman, Kelli, Kubis, Sherri, Kustka, Lucinda, Kwok, Jeni, Kyo, Michihito, Landry, Luis Martín, Latifi, Samir, Lawton-Woodhall, Angela, Lillie, Jon, Lin, John C., Llorente de la Fuente, Ana M., Lopez Alarcón, Yurika Paola, López Fernández, Yolanda, Lopez-Herce, Jesús, Lum, Lucy Chai See, Macrae, Duncan, Maddux, Aline B., Madurga Revilla, Paula, Mahapatra, Sidharth, Maria, Matthieu, Martínez, Lidia, Martinez de Azagra, Amelia, Martínez León, Alejandro Fabio, Mazzillo Vega, Liliana, McCorkell, Jenni, McIntyre, Karen, Medina, Tania, Medina, Alberto, Mellish, Christie, Mendizabal, Mikel, Merritt, Courtney, Mildner, Reinout, Milesi, Christophe, Modesto I Alapont, Vicent, Monjes, Cecilia, Monjure, Tracey, Montes, María José, Morales Martinez, Antonio, Morgan, Ryan, Morzov, Rica, Mourani, Peter M., Murkowski, Kathy, Murphy, Marie, Napolitano, Natalie, Nerheim, Dan, Nett, Sholeen T., Newth, Christopher, Nofziger, Ryan, Nunez, Maria Jose, Ohshimo, Shinichiro, Onate Vergara, Eider, Ongun, Ebru A, Orqueda, Daniel, Oruganti, Siva, Pagowska-Klimek, Izabela, Palanca Arias, Daniel, Pappachan, Jon, Pardo Carrero, Rosalba, Parker, Margaret M., Parrilla, Julio, Patankar, Nikhil, Pávez Madrid, Paula, Payen, Valerie, Paziencia, Fernando, Pedraza, Claudia, Perez Lozano, Germán, Pilar Orive, Javier, Piñeres Olave, Byron Enrique, Pintimalla, Alyssa, Pinto, Neethi, Plunkett, Adrian, Pon, Steve, Pons Odena, Marti, Poterala, Rossana, Qiao, Haiping, Quiñonez Lopez, Deyanira, Ralston, Kimberly, Ramirez Cortez, Grimaldo, Ratiu, Anna, Rea, Miriam, Reyes Dominguez, Susana, Rodgers, Chiara, Rodriguez Campoy, Patricia, Ronan, Laurie, Rosemary, Deheza, Rowan, Courtney, Sadasivam, Kalaimaran, Sanchez Diaz, Juan Ignacio, Sanders, Ron, Santanelli, James, Sapru, Anil, Schneider, James, Sforza, Jesica, Shea, Sara, Shein, Steven L., Sherring, Claire, Sheward, Victoria, Shime, Nobuaki, Shukla, Avani, Siaba Serrate, Alejandro, Sierra, Yamila, Sikora, Lindsay, Silvestre, Catarina, Singleton, Marcy, Sloniewsky, Daniel, Smith, Rebecca, Smith, Lincoln, Song, Hanqiu, Sousa Moniz, Marta, Spaeder, Michael, Spear, Debbie, Spinella, Philip, Starck, Julie, Stoneman, Erin, Su, Felice, Subramanian, Gayathri, Sullivan, Erin, Sundararajan, Santosh, Sweberg, Todd, Sykes, Kim, Tabata, Yuichi, Tai, Chian Wern, Tala, Joana, Tang, Swee Fong, Tantalean, José, Taylor, Ryan, Thomas, Neal, Tibby, Shane, Tieves, Kelly S, Torero, Luis, Torres, Silvio Fabia, Totapally, Balagangadhar, Travert, Brendan, Truemper, Edward, Turón, Gonzalo, Typpo, Katri, Valle, Juan Ramón, Vargas G, Sonia I, Vasquez Hoyos, Pablo, Vasquez Miranda, Daniel, Vavrina, Martin, Vidal, Nilda Águeda, Virk, Manpreet, Walsh, Laura, Wegner Araya, Adriana, Weitz, James, Wellisch, Lawren, Wellman, Paul, Willson, Douglas, Woods, Katherine, Yehya, Nadir, Yerovi, Rocio, Yunger, Toni, Zuluaga Orrego, Cesar, Zurek, Jiri, Khemani, Robinder G, Lopez-Fernandez, Yolanda M, Klein, Margaret J, Kneyber, Martin C J, Fernandez, Analia, Newth, Christopher J L, and Thomas, Neal J

Published
2019
Full Text
View/download PDF

26. Innate Immune Function Predicts the Development of Nosocomial Infection in Critically Injured Children

Author

Muszynski, Jennifer A, Nofziger, Ryan, Greathouse, Kristin, Nateri, Jyotsna, Hanson-Huber, Lisa, Steele, Lisa, Nicol, Kathleen, Groner, Jonathan I, Besner, Gail E, Raffel, Corey, Geyer, Susan, El-Assal, Osama, and Hall, Mark W

Subjects
Pediatric Cancer, Physical Injury - Accidents and Adverse Effects, Pediatric, Cancer, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Adolescent, Child, Child, Preschool, Critical Illness, Cross Infection, Female, Humans, Immunity, Innate, Infant, Longitudinal Studies, Male, Prognosis, Prospective Studies, Wounds and Injuries, Trauma, suppression, complications, TNF-alpha, pediatric, PICU, Clinical Sciences, Emergency & Critical Care Medicine
Abstract

BackgroundCritical injury has been associated with reduction in innate immune function in adults, with infection risk being related to degree of immune suppression. This relationship has not been reported in critically injured children.HypothesisInnate immune function will be reduced in critically injured children, and the degree of reduction will predict the subsequent development of nosocomial infection.MethodsChildren (≤18 years old) were enrolled in this longitudinal, prospective, observational, single-center study after admission to the pediatric intensive care unit following critical injury, along with a cohort of outpatient controls. Serial blood sampling was performed to evaluate plasma cytokine levels and innate immune function as measured by ex vivo lipopolysaccharide-induced tumor necrosis factor α (TNF-α) production capacity.ResultsSeventy-six critically injured children (and 21 outpatient controls) were enrolled. Sixteen critically injured subjects developed nosocomial infection. Those subjects had higher plasma interleukin 6 and interleukin 10 levels on posttrauma days 1-2 compared with those who recovered without infection and outpatient controls. Ex vivo lipopolysaccharide-induced TNF-α production capacity was lower on posttrauma days 1-2 (P = 0.006) and over the first week following injury (P = 0.04) in those who went on to develop infection. A TNF-α response of less than 520 pg/mL at any time in the first week after injury was highly associated with infection risk by univariate and multivariate analysis. Among transfused children, longer red blood cell storage age, not transfusion volume, was associated with lower innate immune function (P < 0.0001). Trauma-induced innate immune suppression was reversible ex vivo via coculture of whole blood with granulocyte-macrophage colony-stimulating factor.ConclusionsTrauma-induced innate immune suppression is common in critically injured children and is associated with increased risks for the development of nosocomial infection. Potential exacerbating factors, including red blood cell transfusion, and potential therapies for pediatric trauma-induced innate immune suppression are deserving of further study.

Published
2014

29. Association of Asthma With Treatments and Outcomes in Children With Critical Influenza

Author

Maddux, Aline B., primary, Grunwell, Jocelyn R., additional, Newhams, Margaret M., additional, Chen, Sabrina R., additional, Olson, Samantha M., additional, Halasa, Natasha B., additional, Weiss, Scott L., additional, Coates, Bria M., additional, Schuster, Jennifer E., additional, Hall, Mark W., additional, Nofziger, Ryan A., additional, Flori, Heidi R., additional, Gertz, Shira J., additional, Kong, Michele, additional, Sanders, Ronald C., additional, Irby, Katherine, additional, Hume, Janet R., additional, Cullimore, Melissa L., additional, Shein, Steven L., additional, Thomas, Neal J., additional, Miller, Kristen, additional, Patel, Manish, additional, Fitzpatrick, Anne M., additional, Phipatanakul, Wanda, additional, Randolph, Adrienne G., additional, Murdock, Meghan, additional, Hefley, Glenda, additional, Maddux, Aline B., additional, Mourani, Peter M., additional, Van, Kevin A., additional, Mansour, Rachel, additional, Miller, Kristen R., additional, Shukla, Avani, additional, Chavez, Jairo, additional, Jung, Emily, additional, Dahmer, Mary K., additional, Jayachandran, Chaandini, additional, Goertzen, Lexie, additional, Faanes, Brittany, additional, Bledsoe, Megan C., additional, Clark, Shannon E., additional, Wellman, Rachel L., additional, Twinem, Nicole, additional, Rasal, Rajashri, additional, Flowers, Maggie, additional, Steele, Lisa, additional, Bush, Jenny L., additional, Burnett, Ryan H., additional, Spear, Debra, additional, Stewart, Laura S., additional, Lynch, Tricia L., additional, and Patel, Manish M., additional

Published
2023
Full Text
View/download PDF

30. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months--17 States, July 2021-January 2022

Author

Halasa, Natasha B., Olson, Samantha M., Staat, Mary A., Newhams, Margaret M., Price, Ashley M., Boom, Julie A., Sahni, Leila C., Cameron, Melissa A., Pannaraj, Pia S., Bline, Katherine E., Bhumbra, Samina S., Bradford, Tamara T., Chiotos, Kathleen, Coates, Bria M., Cullimore, Melissa L., Cvijanovich, Natalie Z., Flori, Heidi R., Gertz, Shira J., Heidemann, Sabrina M., Hobbs, Charlotte V., Hume, Janet R., Irby, Katherine, Kamidani, Satoshi, Kong, Michele, Levy, Emily R., Mack, Elizabeth H., Maddux, Aline B., Michelson, Kelly N., Nofziger, Ryan A., Schuster, Jennifer E., Schwartz, Stephanie P., Smallcomb, Laura, Tarquinio, Keiko M., Walker, Tracie C., Zinter, Matt S., Gilboa, Suzanne M., Polen, Kara N., Campbell, Angela P., Randolph, Adrienne G., and Patel, Manish M.

Subjects
United States. National Institutes of Health, Vaccination, Breast feeding, Infants, Messenger RNA, Health, Children's Hospital (Boston, Massachusetts), Children's Hospital of Philadelphia
Abstract

On February 15, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). COVID-19 vaccination is recommended for persons who are pregnant, breastfeeding, trying to [...]

Published
2022

31. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years--United States, July-December 2021

Author

Zambrano, Laura D., Newhams, Margaret M., Olson, Samantha M., Halasa, Natasha B., Price, Ashley M., Boom, Julie A., Sahni, Leila C., Kamidani, Satoshi, Tarquinio, Keiko M., Maddux, Aline B., Heidemann, Sabrina M., Bhumbra, Samina S., Bline, Katherine E., Nofziger, Ryan A., Hobbs, Charlotte V., Bradford, Tamara T., Cvijanovich, Natalie Z., Irby, Katherine, Mack, Elizabeth H., Cullimore, Melissa L., Pannaraj, Pia S., Kong, Michele, Walker, Tracie C., Gertz, Shira J., Michelson, Kelly N., Cameron, Melissa A., Chiotos, Kathleen, Maamari, Mia, Schuster, Jennifer E., Orzel, Amber O., Patel, Manish M., Campbell, Angela P., and Randolph, Adrienne G.

Subjects
United States. Food and Drug Administration, United States. Centers for Disease Control and Prevention, Pfizer Inc., Vaccination, Messenger RNA, Infection, Health, Children's Hospital (Boston, Massachusetts), Children's Hospital of Philadelphia, Comirnaty (Vaccine)
Abstract

On January 7, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). Multisystem inflammatory syndrome in children (MIS-C) is a severe postinfectious hyperinflammatory condition, [...]

Published
2022

32. 704: LUNG-PROTECTIVE VENTILATION ADHERENCE IN CHILDREN WITH PARDS AND LOWER RESPIRATORY TRACT INFECTION

Author

Polikoff, Lee, primary, White, Benjamin, additional, Bhalla, Anoopindar, additional, Rotta, Alexandre, additional, Izquierdo, Ledys, additional, Sandoval, Alicia, additional, Nofziger, Ryan, additional, Castellani, Pablo, additional, Watson, Christopher, additional, Pon, Steven, additional, Karsies, Todd, additional, and Shein, Steven, additional

Published
2022
Full Text
View/download PDF

34. Factors Associated With COVID-19 Non-vaccination in Adolescents Hospitalized Without COVID-19

Author

Sahni, Leila C, primary, Price, Ashley M, additional, Olson, Samantha M, additional, Newhams, Margaret M, additional, Pannaraj, Pia S, additional, Maddux, Aline B, additional, Halasa, Natasha B, additional, Bline, Katherine E, additional, Cameron, Melissa A, additional, Schwartz, Stephanie P, additional, Walker, Tracie C, additional, Irby, Katherine, additional, Chiotos, Kathleen, additional, Nofziger, Ryan A, additional, Mack, Elizabeth H, additional, Smallcomb, Laura, additional, Bradford, Tamara T, additional, Kamidani, Satoshi, additional, Tarquinio, Keiko M, additional, Cvijanovich, Natalie Z, additional, Schuster, Jennifer E, additional, Bhumbra, Samina S, additional, Levy, Emily R, additional, Hobbs, Charlotte V, additional, Cullimore, Melissa L, additional, Coates, Bria M, additional, Heidemann, Sabrina M, additional, Gertz, Shira J, additional, Kong, Michele, additional, Flori, Heidi R, additional, Staat, Mary A, additional, Zinter, Matt S, additional, Hume, Janet R, additional, Chatani, Brandon M, additional, Gaspers, Mary G, additional, Maamari, Mia, additional, Randolph, Adrienne G, additional, Patel, Manish M, additional, and Boom, Julie A, additional

Published
2022
Full Text
View/download PDF

35. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years--United States, June-September 2021

Author

Olson, Samantha M., Newhams, Margaret M., Halasa, Natasha B., Price, Ashley M., Boom, Julie A., Sahni, Leila C., Irby, Katherine, Walker, Tracie C., Schwartz, Stephanie P., Pannaraj, Pia S., Maddux, Aline B., Bradford, Tamara T., Nofziger, Ryan A., Boutselis, Benjamin J., Cullimore, Melissa L., Mack, Elizabeth H., Schuster, Jennifer E., Gertz, Shira J., Cvijanovich, Natalie Z., Kong, Michele, Cameron, Melissa A., Staat, Mary A., Levy, Emily R., Chatani, Brandon M., Chiotos, Kathleen, Zambrano, Laura D., Campbell, Angela P., Patel, Manish M., and Randolph, Adrienne G.

Subjects
United States. Food and Drug Administration, Pfizer Inc., Vaccination, Messenger RNA, Hospital patients, Pharmaceutical industry, Health, Children's Hospital (New Orleans, Louisiana), Children's Hospital (Boston, Massachusetts)
Abstract

On October 19, 2021, this report was posted as an MMWR Early Release on the MMWR website (https:llwww.cdc.gov/mmwr). Pfizer-BioNTech COVID-19 vaccine is authorized for use in children and adolescents aged [...]

Published
2021

36. Effectiveness of Maternal mRNA COVID-19 Vaccination During Pregnancy Against COVID-19–Associated Hospitalizations in Infants Aged <6 Months During SARS-CoV-2 Omicron Predominance — 20 States, March 9, 2022–May 31, 2023.

Author

Simeone, Regina M., Zambrano, Laura D., Halasa, Natasha B., Fleming-Dutra, Katherine E., Newhams, Margaret M., Wu, Michael J., Orzel-Lockwood, Amber O., Kamidani, Satoshi, Pannaraj, Pia S., Irby, Katherine, Maddux, Aline B., Hobbs, Charlotte V., Cameron, Melissa A., Boom, Julie A., Sahni, Leila C., Kong, Michele, Nofziger, Ryan A., Schuster, Jennifer E., Crandall, Hillary, and Hume, Janet R.

Subjects
CORONAVIRUS diseases, VACCINATION, PREGNANCY, HOSPITAL care, INFANT care
Abstract

Infants aged <6 months are not eligible for COVID-19 vaccination. Vaccination during pregnancy has been associated with protection against infant COVID-19–related hospitalization. The Overcoming COVID-19 Network conducted a case-control study during March 9, 2022–May 31, 2023, to evaluate the effectiveness of maternal receipt of a COVID-19 vaccine dose (vaccine effectiveness [VE]) during pregnancy against COVID-19–related hospitalization in infants aged <6 months and a subset of infants aged <3 months. VE was calculated as (1 – adjusted odds ratio) x 100% among all infants aged <6 months and <3 months. Case-patients (infants hospitalized for COVID-19 outside of birth hospitalization and who had a positive SARS-CoV-2 test result) and control patients (infants hospitalized for COVID-19–like illness with a negative SARS-CoV-2 test result) were compared. Odds ratios were determined using multivariable logistic regression, comparing the odds of receipt of a maternal COVID-19 vaccine dose (completion of a 2-dose vaccination series or a third or higher dose) during pregnancy with maternal nonvaccination between case- and control patients. VE of maternal vaccination during pregnancy against COVID-19–related hospitalization was 35% (95% CI = 15%–51%) among infants aged <6 months and 54% (95% CI = 32%–68%) among infants aged <3 months. Intensive care unit admissions occurred in 23% of all case-patients, and invasive mechanical ventilation was more common among infants of unvaccinated (9%) compared with vaccinated mothers (1%) (p = 0.02). Maternal vaccination during pregnancy provides some protection against COVID-19–related hospitalizations among infants, particularly those aged <3 months. Expectant mothers should remain current with COVID-19 vaccination to protect themselves and their infants from hospitalization and severe outcomes associated with COVID-19. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Variation in Early Anakinra Use and Short‐Term Outcomes in Multisystem Inflammatory Syndrome in Children.

Author

Chang, Joyce C., Young, Cameron C., Muscal, Eyal, Sexson Tejtel, Sara K., Newhams, Margaret M., Kucukak, Suden, Crandall, Hillary, Maddux, Aline B., Rowan, Courtney M., Halasa, Natasha B., Harvey, Helen A., Hobbs, Charlotte V., Hall, Mark W., Kong, Michele, Aguiar, Cassyanne L., Schuster, Jennifer E., Fitzgerald, Julie C., Singh, Aalok R., Wellnitz, Kari, and Nofziger, Ryan A.

Subjects
THERAPEUTIC use of cytokines, VASOCONSTRICTORS, C-reactive protein, GLUCOCORTICOIDS, RELATIVE medical risk, MULTISYSTEM inflammatory syndrome, CONFIDENCE intervals, RETROSPECTIVE studies, IMMUNOMODULATORS, MEDICAL care, TREATMENT effectiveness, INTRAVENOUS immunoglobulins, CARDIOVASCULAR system, LONGITUDINAL method, CHILDREN
Abstract

Objective: Evidence regarding effectiveness of interleukin‐1 receptor antagonism in multisystem inflammatory syndrome in children (MIS‐C) is lacking. We characterized variation in initial treatment with anakinra and evaluated cardiovascular outcomes associated with adding anakinra to standard initial therapy. Methods: We conducted a retrospective cohort study of MIS‐C cases in a US surveillance registry from November 2020 to December 2021. Day 0 was the first calendar day of immunomodulatory treatment. Factors associated with initial anakinra use (days 0–1) were identified. We compared cases in patients ages 2–20 years receiving intravenous immunoglobulin (IVIG) and glucocorticoids versus anakinra plus IVIG and/or glucocorticoids on days 0–1, using inverse probability weighting to balance disease severity. Primary outcomes were vasopressor requirement on day 3 and impaired left ventricular ejection fraction on days 3–4. The secondary outcome was 50% reduction in C‐reactive protein on day 3. Results: Among 1,516 MIS‐C cases at 44 sites, 193 (13%) patients received anakinra alone or with other immunomodulators as initial treatment (range 0–74% by site). Site accounted for 59% of residual variance in anakinra use. After balancing disease severity, initial treatment with anakinra plus IVIG and/or glucocorticoids (n = 121) versus IVIG plus glucocorticoids (n = 389) was not associated with significant differences in vasopressor requirement (25.6% versus 20.1%, respectively; risk ratio [RR] 1.27 [95% confidence interval (95% CI) 0.88–1.84]), ventricular dysfunction (33.7% versus 25.7%, respectively; RR 1.31 [95% CI 0.98–1.75]), or C‐reactive protein reduction. Conclusion: We identified substantial variation in initial anakinra use in a real‐world population of children with MIS‐C, but no average short‐term improvement in cardiovascular outcomes associated with early addition of anakinra to IVIG and/or glucocorticoids compared to IVIG and glucocorticoids alone. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Paediatric critical COVID-19 and mortality in a multinational prospective cohort

Author

Gonzalez-Dambrauskas, Sebastian, primary, Vasquez-Hoyos, Pablo, additional, Camporesi, Anna, additional, Cantillano, Edwin Mauricio, additional, Dallefeld, Samantha, additional, Dominguez-Rojas, Jesus, additional, Francoeur, Conall, additional, Gurbanov, Anar, additional, Mazzillo-Vega, Liliana, additional, Shein, Steven L., additional, Yock-Corrales, Adriana, additional, Karsies, Todd, additional, Nofziger, Ryan, additional, Ambati, Shashikanth, additional, Kendirli, Tanil, additional, Sanders, Ronald, additional, Polikoff, Lee, additional, Whelan, Siobhan, additional, Castro, Francisca, additional, Beltrán, Claudia, additional, Pardo, Rosalba, additional, Vega, Gonzalo, additional, Yunge, Mauricio, additional, Acevedo, Lorena, additional, Ardila, Ivan Jose, additional, Aranguiz, Diego, additional, Alvarez-Olmos, MarthaI, additional, Fernandez-Sarmiento, Jaime, additional, Figueroa-Vargas, Arieth, additional, Valencia-Benavides, Maribel, additional, Roa, Juan David, additional, Lasso-Palomino, Rubén, additional, Franceschi, Alessia, additional, Venthur, Carina, additional, Gonzalez-Dambrauskas, Sebastian, additional, Ampuero, Camila, additional, Paco-Barral, Jhovana E., additional, Tasayco-Muñoz, Jaime, additional, Domínguez-Rojas, Jesús, additional, Rafael-Patricio, Francisca, additional, Pellegrini, Solana, additional, Zuazaga, Marcela, additional, Brusca, Silvana, additional, Viera, Marisa, additional, Aguilera-Avendano, Vladmir Ivan, additional, Alejandro, F., additional, Martínez, L., additional, Thelma, E., additional, Terán, M., additional, Coronado-Lujan, Mariela, additional, Castro-Mancilla, Fabiola, additional, Diaz-Rubio, Franco, additional, Cinquegrana, Karina, additional, Sandoval, Alicia, additional, Gonzalez, Andrea, additional, Zamora, Marta, additional, Lopez-Alarcon, Yurika, additional, Slöcker-Barrio, María, additional, Urbano-Villaescusa, Javier, additional, Camacho, Humberto, additional, Mazzillo, Liliana, additional, Giraldo, Beatriz, additional, Suarez, Pitas, additional, Cespedes-Lesczinsky, Miguel, additional, Castillo, Jorge Omar, additional, Fabris, Juan Pablo, additional, Paladino, Carolina, additional, Sanabria, Silvia, additional, Urena-Chavarría, Erika, additional, Quispe, Gaudi, additional, Munaico-Abanto, Manuel, additional, Colombo, Miriam, additional, Blanco, Ana Carola, additional, Pineres-Olave, Byron Enrique, additional, Carvajal-Veas, Ricardo, additional, Correa, Patricia, additional, Garcia-De-Jesus, Ricardo, additional, Ferre, Arani, additional, Pietroboni, Pietro, additional, Mauricio-Cantillano, Edwin, additional, Banegas-Pineda, Linda, additional, Casson-Rodriguez, Nils, additional, Cavagnaro, Agustin, additional, Wegner, Adriana, additional, Zemanate, Eliana, additional, Beltran-Zuñiga, Emilce, additional, Suarez, Maria Alejandra, additional, Quiñonez, Deyanira, additional, Valero, Leonardo, additional, Repetur, Alejandra, additional, Castellani, Pablo, additional, Bordogna, Adriana, additional, De-la-Hoz-Pastor, Alfredo, additional, Obando-Belalcazar, Evelyn, additional, Prout, Andrew, additional, Jabornisky, Roberto, additional, Wen, Andy, additional, Coates, Bria, additional, Watson, Christopher, additional, Mack, Elizabeth, additional, Hong, Jahee, additional, Pon, Steven, additional, Dapul, Heda, additional, Shein, Steven, additional, Kangin, Murat, additional, Gertz, Shira, additional, Ducharme-Crevier, Laurence, additional, Harwayne-Gidansky, Ilana, additional, Fonseca-Flores, Marisol, additional, Nunez-Enriquez, Juan Carlos, additional, Leon-Villanueva, Armando, additional, Maria, Ledys, additional, Muisyo, Teddy, additional, and Spaeder, Michael, additional

Published
2022
Full Text
View/download PDF

41. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants

Author

Halasa, Natasha B., primary, Olson, Samantha M., additional, Staat, Mary A., additional, Newhams, Margaret M., additional, Price, Ashley M., additional, Pannaraj, Pia S., additional, Boom, Julie A., additional, Sahni, Leila C., additional, Chiotos, Kathleen, additional, Cameron, Melissa A., additional, Bline, Katherine E., additional, Hobbs, Charlotte V., additional, Maddux, Aline B., additional, Coates, Bria M., additional, Michelson, Kelly N., additional, Heidemann, Sabrina M., additional, Irby, Katherine, additional, Nofziger, Ryan A., additional, Mack, Elizabeth H., additional, Smallcomb, Laura, additional, Schwartz, Stephanie P., additional, Walker, Tracie C., additional, Gertz, Shira J., additional, Schuster, Jennifer E., additional, Kamidani, Satoshi, additional, Tarquinio, Keiko M., additional, Bhumbra, Samina S., additional, Maamari, Mia, additional, Hume, Janet R., additional, Crandall, Hillary, additional, Levy, Emily R., additional, Zinter, Matt S., additional, Bradford, Tamara T., additional, Flori, Heidi R., additional, Cullimore, Melissa L., additional, Kong, Michele, additional, Cvijanovich, Natalie Z., additional, Gilboa, Suzanne M., additional, Polen, Kara N., additional, Campbell, Angela P., additional, Randolph, Adrienne G., additional, and Patel, Manish M., additional

Published
2022
Full Text
View/download PDF

42. BNT162b2 Protection against the Omicron Variant in Children and Adolescents

Author

Price, Ashley M., primary, Olson, Samantha M., additional, Newhams, Margaret M., additional, Halasa, Natasha B., additional, Boom, Julie A., additional, Sahni, Leila C., additional, Pannaraj, Pia S., additional, Irby, Katherine, additional, Bline, Katherine E., additional, Maddux, Aline B., additional, Nofziger, Ryan A., additional, Cameron, Melissa A., additional, Walker, Tracie C., additional, Schwartz, Stephanie P., additional, Mack, Elizabeth H., additional, Smallcomb, Laura, additional, Schuster, Jennifer E., additional, Hobbs, Charlotte V., additional, Kamidani, Satoshi, additional, Tarquinio, Keiko M., additional, Bradford, Tamara T., additional, Levy, Emily R., additional, Chiotos, Kathleen, additional, Bhumbra, Samina S., additional, Cvijanovich, Natalie Z., additional, Heidemann, Sabrina M., additional, Cullimore, Melissa L., additional, Gertz, Shira J., additional, Coates, Bria M., additional, Staat, Mary A., additional, Zinter, Matt S., additional, Kong, Michele, additional, Chatani, Brandon M., additional, Hume, Janet R., additional, Typpo, Katri V., additional, Maamari, Mia, additional, Flori, Heidi R., additional, Tenforde, Mark W., additional, Zambrano, Laura D., additional, Campbell, Angela P., additional, Patel, Manish M., additional, and Randolph, Adrienne G., additional

Published
2022
Full Text
View/download PDF

43. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

Author

Olson, Samantha M., primary, Newhams, Margaret M., additional, Halasa, Natasha B., additional, Price, Ashley M., additional, Boom, Julie A., additional, Sahni, Leila C., additional, Pannaraj, Pia S., additional, Irby, Katherine, additional, Walker, Tracie C., additional, Schwartz, Stephanie P., additional, Maddux, Aline B., additional, Mack, Elizabeth H., additional, Bradford, Tamara T., additional, Schuster, Jennifer E., additional, Nofziger, Ryan A., additional, Cameron, Melissa A., additional, Chiotos, Kathleen, additional, Cullimore, Melissa L., additional, Gertz, Shira J., additional, Levy, Emily R., additional, Kong, Michele, additional, Cvijanovich, Natalie Z., additional, Staat, Mary A., additional, Kamidani, Satoshi, additional, Chatani, Brandon M., additional, Bhumbra, Samina S., additional, Bline, Katherine E., additional, Gaspers, Mary G., additional, Hobbs, Charlotte V., additional, Heidemann, Sabrina M., additional, Maamari, Mia, additional, Flori, Heidi R., additional, Hume, Janet R., additional, Zinter, Matt S., additional, Michelson, Kelly N., additional, Zambrano, Laura D., additional, Campbell, Angela P., additional, Patel, Manish M., additional, and Randolph, Adrienne G., additional

Published
2022
Full Text
View/download PDF

44. BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5–18 Years—United States, July 2021 – April 2022.

Author

Zambrano, Laura D, Newhams, Margaret M, Olson, Samantha M, Halasa, Natasha B, Price, Ashley M, Orzel, Amber O, Young, Cameron C, Boom, Julie A, Sahni, Leila C, Maddux, Aline B, Bline, Katherine E, Kamidani, Satoshi, Tarquinio, Keiko M, Chiotos, Kathleen, Schuster, Jennifer E, Cullimore, Melissa L, Heidemann, Sabrina M, Hobbs, Charlotte V, Nofziger, Ryan A, and Pannaraj, Pia S

Subjects
RESEARCH, COVID-19, MULTISYSTEM inflammatory syndrome, CONFIDENCE intervals, COVID-19 vaccines, TIME, CASE-control method, VACCINE effectiveness, MESSENGER RNA, DESCRIPTIVE statistics, RESEARCH funding, LOGISTIC regression analysis, ODDS ratio, CHILDREN, ADOLESCENCE
Abstract

Background Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood. Methods In a multicenter, case-control, public health investigation of children ages 5–18 years hospitalized from 1 July 2021 to 7 April 2022, we compared the odds of being fully vaccinated (2 doses of BNT162b2 vaccine ≥28 days before hospital admission) between MIS-C case-patients and hospital-based controls who tested negative for SARS-CoV-2. These associations were examined by age group, timing of vaccination, and periods of Delta and Omicron variant predominance using multivariable logistic regression. Results We compared 304 MIS-C case-patients (280 [92%] unvaccinated) with 502 controls (346 [69%] unvaccinated). MIS-C was associated with decreased likelihood of vaccination (adjusted OR [aOR]:.16; 95% CI:.10–.26), including among children ages 5–11 years (aOR:.22; 95% CI:.10–.52), ages 12–18 years (aOR:.10; 95% CI:.05–.19), and during the Delta (aOR:.06; 95% CI:.02–.15) and Omicron (aOR:.22; 95% CI:.11–.42) variant-predominant periods. This association persisted beyond 120 days after the second dose (aOR:.08; 95% CI:.03–.22) in 12–18-year-olds. Among all MIS-C case-patients, 187 (62%) required intensive care unit admission and 280 (92%) vaccine-eligible case-patients were unvaccinated. Conclusions Vaccination with 2 doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5–18 years. Most vaccine-eligible hospitalized patients with MIS-C were unvaccinated. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Factors Associated With COVID-19 Non-vaccination in Adolescents Hospitalized Without COVID-19.

Author

Sahni, Leila C, Price, Ashley M, Olson, Samantha M, Newhams, Margaret M, Pannaraj, Pia S, Maddux, Aline B, Halasa, Natasha B, Bline, Katherine E, Cameron, Melissa A, Schwartz, Stephanie P, Walker, Tracie C, Irby, Katherine, Chiotos, Kathleen, Nofziger, Ryan A, Mack, Elizabeth H, Smallcomb, Laura, Bradford, Tamara T, Kamidani, Satoshi, Tarquinio, Keiko M, and Cvijanovich, Natalie Z

Subjects
PARENT attitudes, STATISTICS, CONFIDENCE intervals, COVID-19 vaccines, MULTIVARIATE analysis, AGE distribution, POPULATION geography, INTERVIEWING, ACQUISITION of data, HOSPITAL care of teenagers, SOCIOECONOMIC status, MEDICAL records, DESCRIPTIVE statistics, SOCIAL classes, RESEARCH funding, VACCINATION status, SOCIODEMOGRAPHIC factors, LOGISTIC regression analysis, ODDS ratio, ADOLESCENCE
Abstract

Background Pfizer-BioNTech COVID-19 vaccine received emergency use authorization for persons ≥ 16 years in December 2020 and for adolescents 12–15 years in May 2021. Despite the clear benefits and favorable safety profile, vaccine uptake in adolescents has been suboptimal. We sought to assess factors associated with COVID-19 non-vaccination in adolescents 12–18 years of age. Methods Between June 1, 2021 and April 29, 2022, we assessed factors associated with COVID-19 non-vaccination in hospitalized adolescents ages 12–18 years enrolled in the Overcoming COVID-19 vaccine effectiveness network. Demographic characteristics and clinical information were captured through parent interviews and/or electronic medical record abstraction; COVID-19 vaccination was assessed through documented sources. We assessed associations between receipt of the COVID-19 vaccine and demographic and clinical factors using univariate and multivariable logistic regression and estimated adjusted odds ratios (aOR) for each factor associated with non-vaccination. Results Among 1665 hospitalized adolescents without COVID-19, 56% were unvaccinated. Unvaccinated adolescents were younger (median age 15.1 years vs. 15.4 years, p  < .01) and resided in areas with higher social vulnerability index (SVI) scores (median 0.6 vs 0.5, p  < .001) than vaccinated adolescents. Residence in the Midwest [aOR 2.60 (95% CI: 1.80, 3.79)] or South [aOR 2.49 (95% CI: 1.77, 3.54)] US census regions, rarely or never receiving influenza vaccine [aOR 5.31 (95% CI: 3.81, 7.47)], and rarely or never taking precautions against COVID-19 [aOR 3.17 (95% CI: 1.94, 5.31)] were associated with non-vaccination against COVID-19. Conclusions Efforts to increase COVID-19 vaccination of adolescents should focus on persons with geographic, socioeconomic, and medical risk factors associated with non-vaccination. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. 53: PARDS IN CHILDREN WITH LOWER RESPIRATORY TRACT INFECTION: A BRONCHIOLITIS AND CO-DETECTION SUBSTUDY

Author

White, Benjamin, primary, Polikoff, Lee, additional, Rotta, Alexandre, additional, Gonzalez-Dambrauskas, Sebastian, additional, Izquierdo, Ledys, additional, Sandoval, Alicia, additional, Castellani, Pablo, additional, Watson, Christopher, additional, Nofziger, ryan, additional, Pon, Steven, additional, Karsies, Todd, additional, and Shein, Steven, additional

Published
2021
Full Text
View/download PDF

50. Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children.

Author

Olson, Samantha M, Newhams, Margaret M, Halasa, Natasha B, Feldstein, Leora R, Novak, Tanya, Weiss, Scott L, Coates, Bria M, Schuster, Jennifer E, Schwarz, Adam J, Maddux, Aline B, Hall, Mark W, Nofziger, Ryan A, Flori, Heidi R, Gertz, Shira J, Kong, Michele, Sanders, Ronald C, Irby, Katherine, Hume, Janet R, Cullimore, Melissa L, and Shein, Steven L

Subjects
INFLUENZA treatment, INFLUENZA vaccines, DRUG efficacy, REVERSE transcriptase polymerase chain reaction, CONFIDENCE intervals, TREATMENT effectiveness, DESCRIPTIVE statistics, DATA analysis software, LOGISTIC regression analysis, CHILDREN
Abstract

Background Predominance of 2 antigenically drifted influenza viruses during the 2019–2020 season offered an opportunity to assess vaccine effectiveness against life-threatening pediatric influenza disease from vaccine-mismatched viruses in the United States. Methods We enrolled children aged <18 years admitted to the intensive care unit with acute respiratory infection across 17 hospitals. Respiratory specimens were tested using reverse-transcription polymerase chain reaction for influenza viruses and sequenced. Using a test-negative design, we estimated vaccine effectiveness comparing odds of vaccination in test-positive case patients vs test-negative controls, stratifying by age, virus type, and severity. Life-threating influenza included death or invasive mechanical ventilation, vasopressors, cardiopulmonary resuscitation, dialysis, or extracorporeal membrane oxygenation. Results We enrolled 159 critically ill influenza case-patients (70% ≤8 years; 51% A/H1N1pdm09 and 25% B-Victoria viruses) and 132 controls (69% were aged ≤8 years). Among 56 sequenced A/H1N1pdm09 viruses, 29 (52%) were vaccine-mismatched (A/H1N1pdm09/5A+156K) and 23 (41%) were vaccine-matched (A/H1N1pdm09/5A+187A,189E). Among sequenced B-lineage viruses, majority (30 of 31) were vaccine-mismatched. Effectiveness against critical influenza was 63% (95% confidence interval [CI], 38% to 78%) and similar by age. Effectiveness was 75% (95% CI, 49% to 88%) against life-threatening influenza vs 57% (95% CI, 24% to 76%) against non-life-threating influenza. Effectiveness was 78% (95% CI, 41% to 92%) against matched A(H1N1)pdm09 viruses, 47% (95% CI, –21% to 77%) against mismatched A(H1N1)pdm09 viruses, and 75% (95% CI, 37% to 90%) against mismatched B-Victoria viruses. Conclusions During a season when vaccine-mismatched influenza viruses predominated, vaccination was associated with a reduced risk of critical and life-threatening influenza illness in children. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results